Table 1.
Baseline characteristics of the syntenin-1 high and low groups.
| Clinicopathological variables | Syntenin-1 expression | P value | |
|---|---|---|---|
| Low expression (n = 92) | High expression (n = 47) | ||
| Gender; male/female, n | 53/39 | 29/18 | 0.64 |
| Age (year), mean (SD) | 65.5 ± 10.4 | 62.94 ± 10.9 | 0.18 |
| CEA (ng/mL), median (range) | 3 (1–527) | 4 (1–2841) | 0.86 |
| CA19-9 (U/mL), median (range) | 13 (3–12777) | 17 (0–1661) | 0.55 |
| Tumour size (mm), median (range) | 38 (8–120) | 43 (16–100) | 0.50 |
| Location, n | |||
| Colon/rectum | 56/36 | 26/11 | 0.53 |
| Histological grade, n | |||
| Tub1, tub2, pap/por, muc | 90/2 | 38/9 | 0.001 |
| T grade, n | |||
| T0, 1, 2/T3, 4 | 41/51 | 15/32 | 0.20 |
| Lymphatic invasion, n | |||
| Absent/present | 28/64 | 10/37 | 0.25 |
| Venous invasion, n | |||
| Absent/present | 70/22 | 34/13 | 0.68 |
| Lymphatic metastasis, n | |||
| Absent/present | 50/42 | 21/26 | 0.28 |
| Liver metastasis, n | |||
| Absent/present | 86/6 | 39/8 | 0.07 |
| Peritoneum dissemination, n | |||
| Absent/present | 91/1 | 45/2 | 0.26 |
| Lung metastasis, n | |||
| Absent/present | 90/2 | 45/2 | 0.55 |
| Other organ metastasis, n | |||
| Absent/present | 92/0 | 45/2 | 0.11 |
| Stage, n | |||
| 0, I, II/III, IV | 49/43 | 17/30 | 0.056 |
CEA carcinoembryonic antigen, CA cancer antigen.